Maintenance rucaparib after first-line platinum-based chemotherapy in HER2-negative advanced oesophagogastric adenocarcinoma: results from the PLATFORM study [0.03%]
铂类化疗后鲁卡帕尼维持治疗HER2阴性的晚期胃食管腺癌：来自PLATFORM研究的结果
A Gordon,C Fong,L Satchwell et al.
A Gordon et al.
Background: PLATFORM is a prospective, open-label, multicentre, adaptive phase II trial assessing maintenance therapy in patients with advanced HER2-negative oesophagogastric adenocarcinoma after platinum-based first-line...
HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility [0.03%]
早期HER2阳性乳腺癌中HER2 DX的临床应用回顾
S M Tolaney,N Tung,A C Wolff et al.
S M Tolaney et al.
Therapies targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer have substantially improved outcomes. Nevertheless, marked biological and clinical heterogeneity continue to drive variability in prognosis and treat...
Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort [0.03%]
先前接受过免疫治疗不影响广泛期小细胞肺癌患者二线化疗疗效——来自法国真实世界ESME队列的结果
E Gobbini,M H Diallo,C Clément-Duchene et al.
E Gobbini et al.
Background: Extensive-disease small-cell lung cancer (ED-SCLC) is an aggressive disease with limited effective therapeutic options. Clinical trials suggest an additive effect of chemotherapy and immunotherapy in SCLC, alt...
Corrigendum to 'Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE)': [ESMO Open. Volume 10, Issue 2, February 2025, 104126] [0.03%]
“欧盟联合行动：专家网络（JANE）关于欧洲联盟癌症健康网络的‘绿皮书’”的更正说明：[ESMO开放获取期刊. 2025年，第10卷，第2期，104126]
P G Casali,H Antoine-Poirel,S Berrocoso et al.
P G Casali et al.
Published Erratum
ESMO open. 2026 Aug 5;11(9):108358. DOI:10.1016/j.esmoop.2026.108358 2026
Combining circulating tumor cells and tumor-derived extracellular vesicles for prognosis stratification in patients with metastatic breast cancer [0.03%]
联合循环肿瘤细胞和肿瘤来源的外泌体对转移性乳腺癌患者的预后分层
E Nicolò,J L Sandoval,L Foffano et al.
E Nicolò et al.
Background: Treatment strategies for patients with metastatic breast cancer (MBC) are becoming increasingly complex, underscoring the need for reliable biomarkers to inform clinical decision making. Circulating tumor cell...
Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer [0.03%]
FEderayCA研究最终分析：帕妥珠单抗和曲妥珠单抗皮下注射固定剂量联合方案(PH+)联合化疗治疗HER2阳性早期乳腺癌的长期疗效、安全性和药代动力学
C Jackisch,S-A Im,A Mattar et al.
C Jackisch et al.
Background: FeDeriCa (NCT03493854) showed that the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) was noninferior to intravenous (IV) P and H, with comparable total pathologica...
MYC rearrangement improves the predictive efficacy of the double-hit model in newly diagnosed multiple myeloma [0.03%]
MYC重排可改善双打击模型在新诊断多发性骨髓瘤中的预测效力
J Zhao,C Du,J Cui et al.
J Zhao et al.
Background: MYC rearrangement (MYC-R) is a known adverse prognostic factor in multiple myeloma (MM), yet its role in the double-hit model remains undefined. Meanwhile, the prognostic value of MYC gain/amp has not been cle...
Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy [0.03%]
术前新辅助治疗后超灵敏循环肿瘤DNA检测可改善三阴性乳腺癌预后判断
L Cabel,C Lamy,C W Abbott et al.
L Cabel et al.
Background: Current treatment guidelines for patients diagnosed with stage II to III triple-negative breast cancer (TNBC) rely on the use of neoadjuvant therapy (NAT). A critical unmet need is a sensitive test that can in...
Era-specific prognostic factors and an interpretable machine-learning survival model for renal cell carcinoma brain metastases [0.03%]
肾细胞癌脑转移的特定预后因素和可解释的机器学习生存模型
S Ozgul,Z F Akpinar,D Suki et al.
S Ozgul et al.
Background: Brain metastases (BM) in renal cell carcinoma (RCC) are associated with poor prognosis and limited clinical guidance. We aimed to identify prognostic factors for overall survival (OS) in RCC BM and develop an ...
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02 [0.03%]
针对HER2表达型胆道或胰腺肿瘤患者的曲妥珠单抗德鲁汀的安全性与有效性：DESTINY-PanTumor02亚组分析
D-Y Oh,I Ługowska,D Stroyakovskiy et al.
D-Y Oh et al.
Background: In DESTINY-PanTumor02 Part 1, trastuzumab deruxtecan (T-DXd) demonstrated a clinically meaningful benefit in human epidermal growth factor receptor 2 (HER2)-expressing tumors. In this article, we report subgro...